Suven Life Sciences Ltd

Suven Life Scie. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Suven Life Sciences Ltd

₹ 105 -1.51%
08 May - close price
suven.com BSE: 530239 NSE : SUVEN
About

Suven Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel therapeutics for the treatment of neurodegenerative disorders.[1]

Key Points

Primary Focus
The company has been working towards developing new molecules/ compounds in the complex CNS (central nervous system) space. [1]
Most of its lead molecules address the niche areas of cognitive impairments such as amnesia, dementia, narcolepsy, Alzheimer's, delirium, etc. [2]
CNS is the 2nd largest therapeutic category in the pharmaceutical industry and is also one of the fastest growing segments. [3]

Website BSE NSE
  • Market Cap ₹ 2,282 Cr.
  • Current Price ₹ 105
  • High / Low ₹ 129 / 55.0
  • Stock P/E
  • Book Value ₹ 12.4
  • Dividend Yield 0.00 %
  • ROCE -35.0 %
  • ROE -34.9 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Stock is trading at 8.45 times its book value
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -47.2% over past five years.
  • Company has a low return on equity of -56.8% over last 3 years.
  • Company's cost of borrowing seems high
  • Working capital days have increased from 1,024 days to 2,494 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
2 2 1 4 4 4 4 3 3 4 3 2 2
23 45 29 37 24 25 26 55 34 32 27 49 33
Operating Profit -22 -43 -28 -32 -20 -21 -22 -52 -32 -28 -24 -46 -30
OPM % -1,383% -2,118% -2,340% -733% -467% -596% -494% -1,719% -1,208% -737% -768% -1,885% -1,267%
1 5 0 0 0 6 0 2 6 6 13 6 4
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 1 1 1 1 1 2 2 2 2 2 2 2 2
Profit before tax -22 -39 -28 -34 -21 -16 -23 -51 -28 -24 -13 -42 -28
Tax % -0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 4%
-22 -39 -28 -34 -21 -16 -23 -51 -28 -24 -13 -42 -27
EPS in Rs -1.13 -2.05 -1.48 -1.76 -0.95 -0.75 -1.06 -2.34 -1.27 -1.10 -0.58 -1.91 -1.22
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2007 Mar 2008 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
112 117 521 499 543 625 286 13 13 12 14 12
96 105 361 398 414 427 300 128 93 134 139 140
Operating Profit 16 13 159 102 129 198 -14 -116 -80 -122 -126 -128
OPM % 15% 11% 31% 20% 24% 32% -5% -917% -593% -1,032% -928% -1,095%
1 3 9 19 21 23 27 14 8 5 14 29
Interest 3 5 5 6 6 5 2 1 1 1 1 0
Depreciation 4 4 12 18 21 21 11 4 4 4 7 6
Profit before tax 11 6 152 98 123 196 0 -106 -77 -122 -118 -106
Tax % -5% -32% 28% 26% 29% 37% 15,038% 11% 7% 0% 0% 1%
11 8 109 72 87 124 -24 -94 -72 -122 -118 -105
EPS in Rs 0.65 0.48 5.70 3.76 4.57 6.48 -1.25 -4.94 -3.78 -5.59 -5.42 -4.82
Dividend Payout % 26% 35% 7% 35% 15% 15% -80% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: -47%
3 Years: -5%
TTM: -14%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: -24%
TTM: 11%
Stock Price CAGR
10 Years: 34%
5 Years: 45%
3 Years: 4%
1 Year: 81%
Return on Equity
10 Years: %
5 Years: -57%
3 Years: -57%
Last Year: -35%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2007 Mar 2008 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 6 12 13 13 13 13 13 13 13 15 22 22
Reserves 96 95 547 583 654 755 226 131 58 82 354 248
41 55 109 83 71 34 3 6 5 3 2 1
30 38 105 74 78 118 62 33 53 9 12 14
Total Liabilities 173 199 773 751 816 919 303 182 128 108 389 285
96 110 172 305 306 308 22 25 21 38 37 28
CWIP 5 4 107 7 10 25 0 0 5 4 0 0
Investments 5 2 0 0 301 279 223 0 0 45 46 76
68 83 494 439 199 308 58 157 103 22 305 181
Total Assets 173 199 773 751 816 919 303 182 128 108 389 285

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2007 Mar 2008 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
16 4 143 68 109 70 -53 -135 -96 -128 -103 -83
-20 -16 -110 -39 -311 -1 30 146 56 -22 -261 62
13 6 179 -68 -30 -52 5 3 35 146 396 -1
Net Cash Flow 8 -7 212 -39 -232 17 -18 14 -5 -4 32 -22

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2007 Mar 2008 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 53 111 28 39 31 36 3 66 48 40 22 40
Inventory Days 197 200 165 183 222 329 0
Days Payable 73 157 89 78 91 134
Cash Conversion Cycle 177 154 105 144 162 231 3 66 48 40 22 40
Working Capital Days 107 139 69 73 63 100 23 734 1,139 285 293 2,494
ROCE % 11% 8% 13% 15% 24% -4% -54% -68% -143% -53%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
60.00% 60.00% 60.00% 64.98% 64.98% 64.98% 69.56% 69.56% 69.56% 69.56% 69.56% 69.56%
0.41% 0.44% 0.52% 0.45% 0.45% 0.48% 0.46% 0.51% 0.48% 0.50% 0.54% 0.46%
0.44% 0.44% 0.44% 0.46% 0.39% 0.12% 0.11% 0.11% 0.08% 0.01% 0.01% 1.05%
39.15% 39.12% 39.04% 34.11% 34.18% 34.41% 29.85% 29.80% 29.88% 29.92% 29.88% 28.91%
No. of Shareholders 86,00881,47580,19581,03981,03880,11680,83878,63476,29180,95374,00368,959

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls